A Comparative study on the effect of micronized progesterone and oral dydrogesterone in the treatment of threatened abortion in a tertiary medical center from 2015 to 2019 / Denise Elaine A. Reyes; Lylah Reyes; Elizabeth Ahyong-Reyes.

Contributor(s):

Language: english Publication details: Fairview, Quezon City: Department of Obstetrics and Gynecology, FEU-NRMF, 2021.Description: 40 pages: illustrations, tables; (in folder) + with flash drive (soft copy)Content type:

text

Media type:

unmediated

Carrier type:

volume

Subject(s):

LOC classification:

OB 2021 0002

Summary: Abstract: Threatened abortion occurs in 15% of pregnancies. If not prevented this may lead to pregnancy loss in 20% of cases. But with its resolution, it may lead to a better pregnancy outcome. Progesterone plays a key role in the prevention and management of threated abortion. To determine whether vaginal micronized progesterone is comparable with oral dydrogesterone in the treatment of Threatened abortion. This is a retrospective cohort study involving 573 charts of pregnant patients with threatened abortion who were either given oral dydrogesterone or vaginal micronized progesterone as treatment. Both out- and in-patient charts were reviewed and data extracted by the primary investigator. Baseline maternal characteristics gathered were compared between the two arms. The resolution of symptoms, duration of treatment, occurrence of adverse effects and pregnancy outcome were compared and analyzed between the type of progesterone using chi square and t-test. The resolution of signs and/or symptoms for patients with threatened abortion was not significantly different between those given vaginal micronized progesterone versus those who took oral dydrogesterone (p=0.401). The length of treatment ranged from 7 to 14 days to achieve resolution of signs and/or symptoms. A significantly higher proportion of cases in the oral dydrogesterone arm had nausea and somnolence, while increased vaginal discharge was noted in the vaginal progesterone group (p=0.001). The use of vaginal micronized progesterone and oral dydrogesterone achieved resolution of signs and/or symptoms of threatened abortion generally within 7 days but can be extended for 14 days. Systemic adverse effects of nausea and somnolence were more common in oral dydrogesterone. With micronized progesterone, because of its route of administration, vaginal discharge was more often observed.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Call number	Status	Notes	Date due	Barcode
Room Use	Far Eastern University - Nicanor Reyes Medical Foundation Research	OB 2021 0002 (Browse shelf(Opens below))	Available	with flash drive (soft copy)		R000839

Includes appendices and bibliographical references.

Abstract: Threatened abortion occurs in 15% of pregnancies. If not prevented this may lead to pregnancy loss in 20% of cases. But with its resolution, it may lead to a better pregnancy outcome. Progesterone plays a key role in the prevention and management of threated abortion. To determine whether vaginal micronized progesterone is comparable with oral dydrogesterone in the treatment of Threatened abortion. This is a retrospective cohort study involving 573 charts of pregnant patients with threatened abortion who were either given oral dydrogesterone or vaginal micronized progesterone as treatment. Both out- and in-patient charts were reviewed and data extracted by the primary investigator. Baseline maternal characteristics gathered were compared between the two arms. The resolution of symptoms, duration of treatment, occurrence of adverse effects and pregnancy outcome were compared and analyzed between the type of progesterone using chi square and t-test. The resolution of signs and/or symptoms for patients with threatened abortion was not significantly different between those given vaginal micronized progesterone versus those who took oral dydrogesterone (p=0.401). The length of treatment ranged from 7 to 14 days to achieve resolution of signs and/or symptoms. A significantly higher proportion of cases in the oral dydrogesterone arm had nausea and somnolence, while increased vaginal discharge was noted in the vaginal progesterone group (p=0.001). The use of vaginal micronized progesterone and oral dydrogesterone achieved resolution of signs and/or symptoms of threatened abortion generally within 7 days but can be extended for 14 days. Systemic adverse effects of nausea and somnolence were more common in oral dydrogesterone. With micronized progesterone, because of its route of administration, vaginal discharge was more often observed.

Research - Department of Obstetrics & Gynecology

There are no comments on this title.

to post a comment.